597 related articles for article (PubMed ID: 11395408)
1. PTEN and myotubularin: novel phosphoinositide phosphatases.
Maehama T; Taylor GS; Dixon JE
Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
[TBL] [Abstract][Full Text] [Related]
2. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease.
Wishart MJ; Dixon JE
Trends Cell Biol; 2002 Dec; 12(12):579-85. PubMed ID: 12495846
[TBL] [Abstract][Full Text] [Related]
3. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
4. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
5. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
6. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.
Besson A; Robbins SM; Yong VW
Eur J Biochem; 1999 Aug; 263(3):605-11. PubMed ID: 10469123
[TBL] [Abstract][Full Text] [Related]
7. [PTEN tumor suppressor: functions as a lipid phosphatase].
Maehama T; Dixon JE
Tanpakushitsu Kakusan Koso; 2000 Oct; 45(14):2405-14. PubMed ID: 11051842
[No Abstract] [Full Text] [Related]
8. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
Marsh DJ; Coulon V; Lunetta KL; Rocca-Serra P; Dahia PL; Zheng Z; Liaw D; Caron S; Duboué B; Lin AY; Richardson AL; Bonnetblanc JM; Bressieux JM; Cabarrot-Moreau A; Chompret A; Demange L; Eeles RA; Yahanda AM; Fearon ER; Fricker JP; Gorlin RJ; Hodgson SV; Huson S; Lacombe D; Eng C
Hum Mol Genet; 1998 Mar; 7(3):507-15. PubMed ID: 9467011
[TBL] [Abstract][Full Text] [Related]
9. The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
Myers MP; Pass I; Batty IH; Van der Kaay J; Stolarov JP; Hemmings BA; Wigler MH; Downes CP; Tonks NK
Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13513-8. PubMed ID: 9811831
[TBL] [Abstract][Full Text] [Related]
10. PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench.
Wishart MJ; Taylor GS; Slama JT; Dixon JE
Curr Opin Cell Biol; 2001 Apr; 13(2):172-81. PubMed ID: 11248551
[TBL] [Abstract][Full Text] [Related]
11. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21.
Dahia PL; FitzGerald MG; Zhang X; Marsh DJ; Zheng Z; Pietsch T; von Deimling A; Haluska FG; Haber DA; Eng C
Oncogene; 1998 May; 16(18):2403-6. PubMed ID: 9620558
[TBL] [Abstract][Full Text] [Related]
12. [Cowden disease].
Sawada T; Hamano N; Suzuki A; Okada T; Mabuchi H
Nihon Rinsho; 2000 Jul; 58(7):1479-83. PubMed ID: 10921327
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Rhei E; Kang L; Bogomolniy F; Federici MG; Borgen PI; Boyd J
Cancer Res; 1997 Sep; 57(17):3657-9. PubMed ID: 9288766
[TBL] [Abstract][Full Text] [Related]
14. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.
Li DM; Sun H
Cancer Res; 1997 Jun; 57(11):2124-9. PubMed ID: 9187108
[TBL] [Abstract][Full Text] [Related]
15. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
Maehama T; Dixon JE
J Biol Chem; 1998 May; 273(22):13375-8. PubMed ID: 9593664
[TBL] [Abstract][Full Text] [Related]
18. [PTEN: a tumor suppressor with original properties].
Roux P
Bull Cancer; 1999 Jun; 86(6):522-5. PubMed ID: 10417424
[TBL] [Abstract][Full Text] [Related]
19. PTEN/MMAC1/TEP1 involvement in primary prostate cancers.
Pesche S; Latil A; Muzeau F; Cussenot O; Fournier G; Longy M; Eng C; Lidereau R
Oncogene; 1998 Jun; 16(22):2879-83. PubMed ID: 9671408
[TBL] [Abstract][Full Text] [Related]
20. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
